Overview

Bioavailability and Tolerability of Fexofenadine Hydrochloride Topical Lotion 1%

Status:
Recruiting
Trial end date:
2022-08-31
Target enrollment:
Participant gender:
Summary
The investigational lotion is envisaged as an short- and long term "Ease & Prevent" monotherapy for adults and children with mild to moderate eczema. With itch representing the most burdensome symptom in eczema, the main objectives with the lotion is fast and efficient itch relief, high tolerability, and high short- and long term safety. This phase 1 study aims to monitor skin tolerability, and how much of the active compound that is absorbed to the bloodstream.
Phase:
Phase 1
Details
Lead Sponsor:
OrchestratePharma GmbH
Collaborators:
Cellix Bio Private Limited
In Vitro Research Solutions Private Limited
VidiLife Clinical Research Associate
Treatments:
Fexofenadine